NCT05554419View on ClinicalTrials.gov

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Arising From Previous Myeloproliferative NeoplasmAcute Myeloid Leukemia Post Cytotoxic TherapySecondary Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine

Given IV or SC

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

DRUG

Cytarabine

Given IV

PROCEDURE

Echocardiography Test

Undergo ECHO

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Venetoclax

Given PO

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH